摘要
目的:探讨复肝春3号方(FGC-3)治疗肝硬化腹水的作用机制。方法:将75只清洁级雄性Wistar大鼠随机分为空白对照组(N组),模型组(M组),FGC-3高、中、低剂量组(G、Z、D组),复方鳖甲软肝片组(F组),采用改良的CCl 4-乙醇综合法制备肝硬化腹水大鼠模型,给予FGC-3及复方鳖甲软肝片对该模型进行干预治疗,观察各组大鼠的一般情况、腹腔积液量、肝功能、肝纤维化指标、NO、ET-1、AQP8及肝脏病理的变化。结果:G、Z、D、F组在消退腹水,改善肝功能及肝纤维化程度,调控血清NO、ET-1、AQP8水平等方面均优于对照组。结论:FGC-3能明显降低肝硬化腹水大鼠血清血管活性物质(NO、ET-1)水平,改善肝功能,上调肝硬化腹水大鼠肝脏水通道蛋白AQP8的表达,可能为其有效治疗肝硬化腹水的作用机制。
Objective:To explore the mechanism of FGC-3 in the treatment of cirrhosis ascites.Methods:Total of 75 male Wistar rats were randomly divided into control group(N group),model group(M group),FGC-3 high,medium and low dose group(G,Z,D group),Fufangbiejiaruanganpian group(group F).The rat model of liver cirrhosis ascites was prepared by modified CCL4-alcohol synthesis.And the model was intervened by FGC-3and Fufangbiejiaruanganpian.The general situation,the amount of ascites,liver function,hepatic fibrosis index,NO,ET-1,AQP8 and liver pathology were observed.Results:The G,Z,D,F group was better than the control group in reducing ascites,improving liver function and liver fibrosis,regulating serum NO,ET-1,AQP8 levels.Conclusion:FGC-3 can significantly reduce the level of serum NO,ET-1,improve liver function,up regulate the expression of AQP8 in liver cirrhosis ascites rats,which may be the effective mechanism for the treatment of liver cirrhosis ascites.
作者
管佳畅
张志威
毛宇湘
GUAN Jia-chang;ZHANG Zhi-wei;MAO Yu-xiang(Department of traditional Chinese medicine,Fourth Hospital of Hebei Medical University,Shijiazhuang Hebei,050011,China;不详)
出处
《中西医结合肝病杂志》
CAS
2021年第10期901-904,共4页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
基金
河北省中医药管理局科研课题(No.2012023)
河北省卫计委科研课题(No.2016027)。
